Floatz logo

azd0120

Systemic Sclerosis

AstraZenecaCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Systemic Sclerosis cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3BB
Iloprost
National Center for Research Resources (NCRR)
Phase 3BB
Bosentan
Actelion
Phase 3B
Rituximab
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3B
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2B

View all 41 →

Same molecule, other indications

azd0120 is also rated in:

plasma cell myelomaActive
B
Indicative · Phase 3
58 / 100
View asset →
idiopathic inflammatory myopathyActive
CC
Indicative · Phase 1
43 / 100
View asset →
rheumatoid arthritisActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →